Zewdu W, Habte B
Department of Internal Medicine, Faculty of Medicine, Addis Abeba University.
Ethiop Med J. 1995 Apr;33(2):95-102.
The efficacy of isradipine, a new antihypertensive dihydropyridine calcium antagonist, was prospectively studied in Ethiopian patients with uncontrolled severe hypertension on multiple antihypertensive agents. Enrolled were 13 patients based on inclusion and exclusion criteria and 12 patients completed the study. The study design included a three-week wash-out period followed by eight weeks of active treatment. Eleven patients (92%) took diuretics in addition to isradipine. Patients were started on 2.5mg of isradipine twice daily and the dose was increased to 5mg twice daily in eight (67%) patients since the diastolic blood pressure (DBP) remained above 90mmHg four weeks after the initiation of therapy. The treatment resulted in a mean decrease of 42mmHg in systolic blood pressure (SBP) (p < 0.0001) and 34mmHg in DBP (p < 0.0001). Seven patients (58%) achieved normalization of DBP and in the remaining 5 (42%) the DBP became less than 105mmHg. Almost all patients experienced mild and transient side effects resulting from vasodilation but all tolerated these except one who dropped out from the study. In conclusion, these results indicate that isradipine combined with a diuretic is a safe and effective antihypertensive agent in Ethiopian patients with uncontrolled hypertension.
对埃塞俄比亚使用多种抗高血压药物仍无法控制严重高血压的患者，前瞻性地研究了新型抗高血压二氢吡啶类钙拮抗剂伊拉地平的疗效。根据纳入和排除标准招募了13名患者，12名患者完成了研究。研究设计包括为期三周的洗脱期，随后是八周的积极治疗期。11名患者（92%）在服用伊拉地平的同时还服用了利尿剂。患者开始时每天两次服用2.5mg伊拉地平，由于治疗开始四周后舒张压（DBP）仍高于90mmHg，8名（67%）患者的剂量增加到每天两次5mg。治疗使收缩压（SBP）平均降低42mmHg（p<0.0001），舒张压降低34mmHg（p<0.0001）。7名患者（58%）舒张压恢复正常，其余5名患者（42%）舒张压降至105mmHg以下。几乎所有患者都经历了由血管舒张引起的轻微和短暂的副作用，但除一名退出研究的患者外，所有患者都能耐受这些副作用。总之，这些结果表明，伊拉地平联合利尿剂对埃塞俄比亚未控制高血压患者是一种安全有效的抗高血压药物。
